Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Otiko is the only current officer associated with Viaderma, all others left when Philips bought the shell company for his wife's art business.
Don't be holding the bag when the music stops.
Just saying...
It's not the naysayers buying shares, it's the back again pumper thinking he can pop a few percentage points and leave another bag-holder in the wake. Someday he too will be holding the bag.
Some people just need to learn to accept the fact that this company and it's product is going nowhere. This is the second attempt to market it in the past 5 years and it's still a dud.
Nothing is coming except for more outstanding shares and lower share prices.
VDRM = The Venus Fly trap.
$JAGX"In Play". Closed with EOD volume spike.
Bravo! Excellent post, well said.
Wait for it... $$$
I now have slops and Otiko in my profile pic. That should get the PPS up.
That's funny. Nope!
Desperation. Originally referring to a gesture of mourning or intense grief, this expression, dating from the 16th century, is no longer used literally. It continues to be said, however, of one who is extremely frustrated, or going through an intensely painful emotional experience.
At the least the Doc isn't dreaming out loud by issuing bogus PR's anymore. Like I said before, there is no price worth paying for a company that is failing. Stay away from VDRM until there is solid, no fluff news. Then maybe consider it. (That's a big maybe).
Triple 000's on the horizon.
Hang in there and soon there will be nothing to talk about. "LOCK"
There is absolutely no price I will pay for a share of VDRM! The only way that I would reenter a position here is that they published, solid non-fluff news. Nothing else will convince me to waste my money holding this POS. It's done, it's toast.
"Some want this to go down" SHM, LOL!
I would think Kasten Inc would but a block in any buy-out plans. They still claim to own the patent rights to Vitastem formula and the courts didn't disagree with them either. Just saying.
Yes, that's exactly what they did. Dr. Otiko became involved with this company to re-launch this product with a revised formula. The first attempt to bring this product to market fizzled out the same way as this attempt. Although I believe Otiko believed in the product whole heartedly, I believe he (and Phillips) knew that it was going to fail, but they also also knew that they would bring in large amounts of money selling shares in the process.
The root problem here is the product. Vitastem works as for what it was developed for, but I believe it is not unique and has a outrageous price point.
If you go way back to December of 2016 when they RS and begun the media blitz's about Diabetic skin ulcer treatment, the diabetic community wasn't buying into the pitch. Otiko was also asked to write an article on the treatment and he failed to do so. This was actually the first sign we were being scammed back in May of 2017.
Also one must look at the fact that Viaderma is nothing more than a licensing company. The lab that produces the product, I believe is Phillips's company and the distributor is 25% owned by Otiko (with the start-up funds came from VDRM) and the accounting firm, the advertisers and business advisors / toxic debt holders all work out of the same building office in Plantation Florida. A questionable business structure to say the least.
In summary, there is nothing about this company that looks attractive as a positive investment, VDRM is simply "Out of favor".
Buyback shares with what, his charm and good looks? The only money he has is the funds derived by diluting your shares.
Relax... I'm sure the Great Doctor Con is closing a big deal in South America as we speak.
SMH
The number of recorded investors has not changed in the three years I've been following VDRM. I view the term recorded shareholders as bag-holders waiting for something that is unlikely to happen. The only thing that moved the PPS up in the past year has been fluff PR and unscrupulous pump and dump cons.
VDRM is a dead investment, period!
I smell something burning.
The best news VDRM shareholders could receive is that Dr. Otiko has been replaced as CEO.
$HEB Insiders exercising warrants and accumulating shares. Very interesting...
Insiders exercising warrants and accumulating shares, Very interesting...
Is this the turning point for HEB? Good news and increasing revenues should move the PPS north. Good luck!
I view today's trading action as a significant reversal in the downward recent trend. I expect we will witness new recent highs over the coming weeks as folks accumulate shares.
This is the problem with a one man operation, he stops, it stops. Where's the sales force that was being hired to bring in business? Yup, all BS.
TNXP was $40+ less then a year ago, Hummmm...
Plenty of possibilities in the works... https://www.otcmarkets.com/filing/html?id=13277416&guid=rL6tUe8-4JN6I3h#EX99-01_HTM
July 12, 2018 is the date of the last PR "Letter to the shareholders" so I wouldn't hold my breath...
I believe the real question is; Why doesn't this product/process catch-on and sell if it is so wonderful? This is not the first time they tried to market it and it petered-out the first time too. Why?
This is why the PPS is down; paying for services with shares and then the receiver sells them for payment while he still can.
NOTE 10 – STOCK BASED COMPENSATION
On January 3, 2018, the Company entered into a services agreement with a consultant for business development and marketing services, pursuant to which the Company agreed to issue the consultant total 20,000,000 shares of common stock of the Company and a convertible promissory note in amount of $48,000 for services rendered (“Brewer Note”). The agreement has a term of one year effective upon the signing date, and the shares shall be issued in 4 installments, or 5,000,000 shares each, starting from the signing date and every 90 days thereafter until total share amount are paid in full. 10,000,000 shares pursuant to this Agreement were issued on March 7, 2018. Accordingly, the Company calculated total fair value of this stock issuance in amount of $135,000, which was determined by the fair value of the Company’s Common Stock on the grant date, at a price of approximately $0.0135 per share, and booked the stock based compensation pro rata for six months. The third payment of 5,000,000 shares were not issued as of the date of this report, the fair value of which in amount of $67,500 was recorded as accrued expenses in the consolidated balance sheet as of September 30, 2018. For the three and nine months ended September 30, 2018, the Company recognized $67,500 and $202,500, respectively, to the consolidated statements of operations.
On March 27, 2018, the Company issued 20,000,000 shares of Common Stock of the Company to 2 consultants for services rendered. The Company recorded total fair value of this stock issuance in amount of $214,000, which was determined by the fair value of the Company’s Common Stock on the grant date, at a price of approximately $0.0107 per share, as stock based compensation during the nine months ended September 30, 2018.
On February 10, 2017, the Company entered into a consulting service agreement with a Consultant for public relationship and marketing services in exchange for 1,000,000 shares of Common Stock of the Company. The agreement had a term of one year effective upon the signing date, but the shares paid to Consultant were not refundable for any reasons. The Agreement was renewed on March 8, 2018 and additional 1,000,000 shares of Common Stock were granted to the same consultant. The fair value of these shares was determined by the fair value of the Company’s Common Stock on the grant dates, at a price of approximately $0.0228 per share and $0.0102 per share, respectively. The 2,000,000 shares were issued during the second quarter of 2018 and $10,200 was recorded as stock based compensation during the nine months ended September 30, 2018.
On April 18, 2018, the Company issued 3,500,000 shares of Common Stock of the Company to a consultant for services rendered. The Company recorded total fair value of this stock issuance in amount of $34,650, which was determined by the fair value of the Company’s Common Stock on the grant date, at a price of approximately $0.0099 per share, as stock based compensation during the nine months ended September 30, 2018.
Ted, thanks for asking. I think they updated the fins because the company is still supplying product to the market. Management needs to maintain minimal requirements to continue to able to draw salaries and accumulate stock for themselves. The product is not selling enough to offset cost, so expect more dilution in the coming months. They still have 300M Authorized available and could always rise the limit as well. I doubt the Doc would R/S seeing that he has been paying himself in common stock. I wouldn't sink another dime into this company until they have solid news and the price begins to move. The only trading game here now is the Pump and Dump on hearsay rumors.
That's where you are wrong, poor performance has held this stock down. Go ahead and fluff it up so you can scalp a couple of points from unsuspecting traders.
They don't care about others, it's about scalping a few points for their beer money gains. This is why it won't run without heavy volume, they kill it before it can get started.
Opposed to attacking me for my point of view, how about you share with us all the great things happening today with Viaderma?
Do yourself a big favor and donate your money to a good charity, at least you can write-off the whole amount.
Thinking about it, but I think the timing is wrong right now. No news will drive the PPS back to the low $.0020's in a heartbeat. The ad I saw on FB had no direct connection to K.K. other then she was talking about acne and never mentioned the product in her statement. I just feel if I buy back in I'll be stuck holding the bag again. This maybe the opportunity to cash in shares if you have them. You can let 30 days pass and avoid the wash sale before the EOY statements come out in April.
The bump in activity maybe due to the ad I saw on facebook for Vitastem. They associated their product with Kim Kardashian and her acne history. Maybe that will sell a few dozen bottles of Vitastem.
I don't know what companies you're referring to, because it's not reflected in the earnings statement. I believe Phillips has licensed out the SSP technology, however VDRM wouldn't see any of those royalties. BiogenX is the current supplier of Viastem and I think that's it.